Buy the Dip: AstraZeneca’s Oncology Engine and Pipeline Make Wainua Pullback a Tactical Opportunity
AstraZeneca (AZN) fell after the Phase-3 CARDIO-TTRansform failure for Wainua; the selloff looks larger than the program's economic impact. Strong oncology cash flows, an $80B 2030 revenue target still intact, and upcoming pipeline readouts make a structured long the highest-probability trade here. Entry $168.91, stop $155.00, target $195.00 on a l…